GAGomes as early detection biomarkers: multi-cancer
Recent evidence suggests that metabolic reprogramming of GAGomes is an ubiquitous process in cancers. In a clinical study with over...
Metabolic reprogramming is a hallmark of cancer. Cancer cells need to rewire the way they procure energy and nutrients to support abnormal proliferation and growth. Yet, metabolism is an under-investigated layer of information to identify biomarkers for cancer. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, we identified the profile of human glycosaminoglycans – the GAGome – as the most deregulated panel of metabolites in cancer.
Elypta developed MIRAM® - the first standardized and commercial kits to profile the human GAGome at a high throughput. The kits use UHPLC-MS/MS to quantify 17 GAGome disaccharides encompassing the exhaustive spectrum of modifications observed in the three main classes of human glycosaminoglycans: chondroitin sulfate, heparan sulfate, and hyaluronic acid.
